You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Biotechnology company Inscripta raises $125M in series D round
Street Talk - Ep. 64: Coronavirus jumpstarts digital adoption
Street Talk - Ep. 63: Deal talks continue amid bank M&A freeze, setting up for strong Q4
Street Talk - Ep. 62: 'Brutal' outlook for oil demand offers banks in oil patch no relief
Amid Q1 APAC Fintech Funding Slump, Payment Companies Drove Investments
Inscripta Inc. raised $125 million in its series D funding round, which was led by Paladin Capital Group.
New investors JS Capital Management LLC and Oak HC/FT Partners LLC participated in the round, alongside existing investors.
Inscripta has now raised a total of $259.5 million.
Inscripta is a Boulder, Colo.-based biotechnology company that is developing a benchtop platform for genome-scale engineering.